滚动资讯
FierceBiotech'We need to put some bad ideas to bed': Inside Incubate's battles for biotech on Capitol HillFierceBiotechAfter local tumor approval, Novocure touts positive data in metastatic pancreatic cancerFierceBiotechOtsuka buys Transcend in $1.2B deal, nabbing MDMA analog for psychiatric conditionsFierceBiotechAstraZeneca’s in vivo CAR-T bet eradicates cancer in 3 of 5 patients, but death mars datasetFierceBiotechChutes & Ladders—Tang takes over Aurinia after FDA brouhahaThermo FisherThermo Fisher Scientific collaborates with SHL Medical and expands Ridgefield site - ROI-NJEndpoints NewsAnaptysBio spins out biotech operations; Affibody's data in hidradenitis suppurativaBioPharma DiveNovartis targets Xolair successor in buyout of startup ExcellergyEndpoints NewsFDA approves Rocket's gene therapy for ultra-rare immune diseaseIlluminaVanguard realigns reporting; subsidiaries to report separately (Illumina, ILMN) - Stock TitanEndpoints NewsFDA approves Novo Nordisk's once-weekly insulinBioWorldShanghai Institute of Materia Medica discloses new GLP-1R agonists
Endpoints News 2026年3月27日

FDA approves Rocket's gene therapy for ultra-rare immune disease

FDA approves Rocket's gene therapy for ultra-rare immune disease

原文
暂时没有全文，请查看原始来源。

目录

59 全部